Alnylam’s Amvuttra: A Game-Changer in the Fight Against Transthyretin Amyloidosis with Cardiomyopathy March 21, 2025
Alnylam’s Amvuttra Receives FDA Approval: A Game-Changer in Treating Transthyretin Amyloidosis with Cardiomyopathy March 21, 2025
Alnylam’s Amvuttra: A Game-Changer in the Battle Against Transthyretin Amyloidosis with Cardiomyopathy March 21, 2025
Novartis’s OAV101 Gene Therapy Shows Promising Results in Spinal Muscular Atrophy Trials, Aiming for Expanded Patient Access March 20, 2025
Novartis Unveils Promising Gene Therapy OAV101 for Spinal Muscular Atrophy, Aiming to Expand Treatment Options for Older Children March 20, 2025
Optum Rx to Eliminate Prior Authorization for 80 Medications, Paving the Way for Improved Healthcare Access March 20, 2025
Optum Rx Eliminates Prior Authorization for 80 Medications, Easing Patient Access and Reducing Administrative Burden March 20, 2025
Optum Rx Leads the Charge: Major Policy Shift Eliminates Prior Authorization for 80 Essential Medications March 20, 2025
Optum Rx Abolishes Prior Authorization for 80 Medications, Aiming to Enhance Patient Access and Reduce Administrative Burdens March 19, 2025
Optum Rx Takes Bold Step to Ease Medication Access by Eliminating Prior Authorization for 80 Drugs March 19, 2025
